Apogenix GmbH

General information

Apogenix GmbH
Im Neuenheimer Feld 584
69120 Heidelberg, Baden-Württemberg
Germany

Contact person: Thomas Hoeger, Chief Executive Officer
Company main phone: +49 (6221) 586080
Company main fax: +49 (6221) 5860810
Website: https://www.apogenix.com

Year founded:	2005
Source of foundation:	Spin-off from public institution / NPO
Name of foundation source:	German Cancer Research Center, Heidelberg

Corporate description / mission:
Apogenix develops innovative protein therapeutics for the treatment of solid tumors, malignant hematological diseases, and COVID-19. The company's Asunercept is a CD95 ligand inhibitor that is currently in clinical development for the treatment of cancer. It shows the potential for broad application in the treatment of solid tumors, malignant hematological diseases, and viral infections, such as COVID-19.

State of ownership: Private / independent
Headquarters: HQ: Yes

Categorization

Sector:

Biotechnology - Therapeutics and Diagnostics

Subsector:

Anti-infectives
Immunotherapy
Proteins
Small molecules

Primary therapeutic areas:

Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
Diseases of the eye / ophthalmology
Infectious and parasitic diseases / infectiology / parasitology
Neoplasms / cancer / oncology
Skin and subcutaneous tissue / dermatology

Business model:

Customer segments:

Hospitals
Large biotech & big pharma
Small biotech

Distribution:

Indirect (independent dealer)

Summary Products / Services / Technologies

Number of Biotech Products

Pre-clinical:	5
Phase I:	2
Phase II:	1
Phase III:	1

Description of products:
Asunercept

Technology used:
HERA-Ligand Technology

Collaborations & Clients

Partnering strategy / collaborations:
Apogenix is exploring partnerships with pharmaceutical and biotechnology companies as well as collaborations with leading academic institutions in order to advance the preclinical and clinical development and commercialization of its proprietary drug candidates targeting members of the TNF superfamily and TNF receptor superfamily.